Fda grants breakthrough device designation to guardant health's shield multi-cancer detection (mcd) test

Palo alto, calif.--(business wire)--guardant health, inc. (nasdaq: gh), a leading precision oncology company, today announced that its shield multi-cancer detection (mcd) test has been granted breakthrough device designation from the u.s. food and drug administration (fda). the shield mcd test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 4.
MCD Ratings Summary
MCD Quant Ranking